Journal of the Endocrine Society · 2026
Missed opportunities for risk reduction: type 1 diabetes management in older adults in DPV and T1DX-QI registries.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fantasia Kathryn L, Lanzinger Stefanie, Rompicherla Saketh, Grammes Jennifer J, O'Malley Grenye, Mader Julia K, Golden Lauren, Kopp Florian, Maahs David M, Jehle Peter M, Ebekozien Osagie, Holl Reinhard W
Аннотация
AIMS: To examine prescription of guideline-recommended therapies and achievement of treatment targets across the span of older adulthood in type 1 diabetes (T1D) in the United States and Germany/Austria.
MATERIALS AND METHODS: Cross-sectional data of adults aged ≥60 years with T1D for ≥1 year seen in 2022 in the T1D Exchange Quality Improvement Collaborative (T1DX-QI) and the Diabetes Prospective Follow-up (DPV) registry. Descriptive statistics and within-registry comparisons across age groups using analysis of variance and chi-squared tests were used to analyze the data.
RESULTS: Thirty-six hundred adults aged ≥60 years, median age 67.5 [interquartile range (IQR) 63.4, 72.8] in T1DX-QI (n = 1549) and 68.9 (IQR 63.6, 75.7) in DPV (n = 2051) were included. The prevalence of atherosclerotic cardiovascular disease (ASCVD) (34.6% vs 16.8%) and chronic kidney disease (28.5% vs 11.8%) was higher in the DPV than the T1DX-QI. Lipid-lowering therapy for secondary prevention (52.9% vs 38%) and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use (55.3% vs 44.8%) were higher in the DPV. Continuous glucose monitoring use was similar (50.3% vs 47.9%), insulin pump use was >2 × higher (40.7% vs 17%), and automated insulin delivery use was >3 × higher (20.4% vs 6.4%) in the T1DX-QI as compared to the DPV.
CONCLUSION: Despite a high prevalence of ASCVD and risks of hypoglycemia, guideline-recommended treatments including lipid-lowering therapy for secondary prevention and diabetes technologies were used in approximately half or fewer of older adults with T1D. Additional attention to prescribing and practices to support clinicians and older adults in the use of diabetes technologies is urgently needed.
MATERIALS AND METHODS: Cross-sectional data of adults aged ≥60 years with T1D for ≥1 year seen in 2022 in the T1D Exchange Quality Improvement Collaborative (T1DX-QI) and the Diabetes Prospective Follow-up (DPV) registry. Descriptive statistics and within-registry comparisons across age groups using analysis of variance and chi-squared tests were used to analyze the data.
RESULTS: Thirty-six hundred adults aged ≥60 years, median age 67.5 [interquartile range (IQR) 63.4, 72.8] in T1DX-QI (n = 1549) and 68.9 (IQR 63.6, 75.7) in DPV (n = 2051) were included. The prevalence of atherosclerotic cardiovascular disease (ASCVD) (34.6% vs 16.8%) and chronic kidney disease (28.5% vs 11.8%) was higher in the DPV than the T1DX-QI. Lipid-lowering therapy for secondary prevention (52.9% vs 38%) and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use (55.3% vs 44.8%) were higher in the DPV. Continuous glucose monitoring use was similar (50.3% vs 47.9%), insulin pump use was >2 × higher (40.7% vs 17%), and automated insulin delivery use was >3 × higher (20.4% vs 6.4%) in the T1DX-QI as compared to the DPV.
CONCLUSION: Despite a high prevalence of ASCVD and risks of hypoglycemia, guideline-recommended treatments including lipid-lowering therapy for secondary prevention and diabetes technologies were used in approximately half or fewer of older adults with T1D. Additional attention to prescribing and practices to support clinicians and older adults in the use of diabetes technologies is urgently needed.